I am a medical oncologist who specializes in the treatment of malignancies of the gastrointestinal tract, including esophagus and stomach cancers. My research focuses on the development of new treatments for patients with esophagus and stomach cancers, and I am particularly interested in finding ways to select the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens. I run clinical and translational studies designed to develop a better prevention, early diagnosis, staging, and treatment strategies. I am the Principal Investigator on a number of clinical trials at Memorial Sloan Kettering. My research has been supported by grants from the National Cancer Institute, the American Society of Clinical Oncology (ASCO), and The Society of Memorial Sloan Kettering Cancer Center.
- Clinical Expertise: Gastrointestinal Malignancies; New Chemotherapies; Esophageal and Gastric Cancers
- Languages Spoken: English; Russian
- Education: MD, New York University School of Medicine
- Residencies: NYU Medical Center/Bellevue Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Yelena Y. Janjigian
- A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
- A Phase II Study of FOLFOX plus Regorafenib in Patients with Inoperable or Metastatic Esophageal and/or Stomach Cancer
- A Phase II Study of Nintedanib in Patients with Advanced Esophagogastric Cancer
- A Phase II Study of Regorafenib versus Placebo in Patients with Node-Positive Esophageal Cancer Who Completed Chemotherapy, Radiation Therapy, and Surgery
- A Randomized Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) Treatment versus Conventional DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer